Similar articles

• Potentiating effects of combined usage of three sulfonylurea drugs on the occurrence of alloxan diabetes in rats.

  Katsumata K, Katsumata Y, Ozawa T, Katsumata K Jr. Katsumata K, et al. Horm Metab Res. 1993 Feb;25(2):125-6. doi: 10.1055/s-2007-1002058. Horm Metab Res. 1993. PMID: 8458609 No abstract available.
• Potentiating effect of glibenclamide on the occurrence of alloxan diabetes in rats.

  Katsumata K, Katsumata Y. Katsumata K, et al. Horm Metab Res. 1986 Apr;18(4):277-8. doi: 10.1055/s-2007-1012293. Horm Metab Res. 1986. PMID: 3086202 No abstract available.
• Therapeutical concentrations of tolbutamide, glibenclamide, gliclazide and gliquidone at different glucose levels: in vitro effects on pancreatic A- and B-cell function.

  Gregorio F, Ambrosi F, Cristallini S, Pedetti M, Filipponi P, Santeusanio F. Gregorio F, et al. Diabetes Res Clin Pract. 1992 Dec;18(3):197-206. doi: 10.1016/0168-8227(92)90146-i. Diabetes Res Clin Pract. 1992. PMID: 1289021
• EXPERIMENTAL DIABETES AND THE MODE OF ACTION OF THE SULFONYLUREAS. WITH SOME SPECULATIONS ON THE PREVENTION OF DIABETES.

  FOA PP. FOA PP. Bull Sinai Hosp Detroit. 1964;12:31-46. Bull Sinai Hosp Detroit. 1964. PMID: 14156394 Review. No abstract available.
• Sulfonylurea derivatives and cancer, friend or foe?

  Hendriks AM, Schrijnders D, Kleefstra N, de Vries EGE, Bilo HJG, Jalving M, Landman GWD. Hendriks AM, et al. Eur J Pharmacol. 2019 Oct 15;861:172598. doi: 10.1016/j.ejphar.2019.172598. Epub 2019 Aug 10. Eur J Pharmacol. 2019. PMID: 31408647